Patients in South Korea who are critically ill with COVID-19 will now be administered remdesivir as part of their treatment.
The Korea Centers for Diseases Control said Wednesday that the experimental drug, conventionally used to treat Ebola, will now be available for badly ill COVID-19 patients.
Patients that will be prioritized for remdesivir are those with pneumonia and those in need oxygen.
Details regarding the amount imported and the price were not disclosed as part of the deal between the drugmaker Gilead Sciences and the Korea Centers for Diseases Control.
In a U.S.-government-led study, remdesivir was found to have shortened recovery times by 31 percent.